Project Grant R01CA288833
Award Date
1/2/25
Completion Date
12/31/29
Dollars Obligated
$678K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Arizona State University (ASU) aims to develop MRI-based methods to detect and differentiate two invasive high-grade glioma subtypes - the neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes. The $997,410 award, with a period of performance from December 2024 to November 2029, will leverage advanced diffusion MRI and deuterium MRI techniques to establish quantitative...
This $1,963,241.55 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to improve patient care by optimizing and validating quantitative magnetic resonance imaging (MRI) methods for early prediction of brain cancer response to therapy. The project will implement multi-vendor, spin and gradient echo (SAGE)-based dynamic susceptibility contrast (DSC) MRI protocols, establish automated and open source...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports the development and validation of radiopathomic modeling techniques to improve the characterization and monitoring of glioma brain tumors. The $677,998 award to the Medical College of Wisconsin will enable external validation of radiopathomic mapping algorithms on datasets from multiple institutions, unification and refinement of the models, and a prospective...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop new metabolic therapy and imaging approaches for treating diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The key products and services to be delivered include: Determining if combined inhibition of the enzymes G6PD and...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This $407,113 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development of a new bio-orthogonal mid-infrared photothermal (MIP) imaging approach for studying cancer cell metabolism. The award to Trustees of Boston University will fund three key research efforts over a 3-year period from September 2024 to August 2027: Building a library of nitrile-based molecular probes to sense important metabolic events in cancer cells....
The National Cancer Institute (NCI) awarded a $201,172 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Duke University. The grant aims to develop a non-invasive biomarker for longitudinal molecular profiling of glioblastoma, an aggressive and lethal brain tumor. The research project will utilize cell-free DNA methylation patterns to overcome limitations of current diagnostic approaches that rely on invasive surgical procedures. The grant runs from August 1, 2024 to July...
This Project Grant award for $901,906 from the Defense Health Agency supports research to develop "AUTOMATIC RAPID, HIGH RESOLUTION METABOLIC IMAGING FOR IMPROVED MANAGEMENT OF PATIENTS WITH GLIOMA". The funding is provided through the Military Medical Research and Development program (CFDA 12.420) which focuses on biomedical research to address military and veteran health needs. The research, conducted by the Regents of the University of California, San Francisco (UCSF), aims to...
This $2,020,098 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop an innovative X-ray dual-energy cone-beam microCT (DECB microCT) imaging system for intraoperative quantitative analysis of breast lumpectomy specimens. The objective is to enhance the contrast between breast cancer and normal fibroglandular tissue, enabling improved identification of positive surgical margins during breast-conserving surgery. Key project...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to conduct research on leveraging reactive metabolite generation as a novel therapeutic strategy for patients with isocitrate dehydrogenase-mutant (IDHm) gliomas, a deadly form of brain cancer. The key objectives of this 5-year project are to: 1) determine if the combination of a brain-penetrant glyoxalase 1...